RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

Thu, 29 Oct 2026 06:00:00 -0400

LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its third quarter 2026 financial results on Monday, November 9, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

Thu, 29 Oct 2026 06:00:00 -0400

Truist Securities Reiterates Buy Rating on RadNet (RDNT)

Tue, 27 Oct 2026 09:34:16 -0400

Truist Securities analyst David MacDonald reiterated a Buy rating and $94.00 price target on RadNet (NASDAQ: RDNT).

The analyst commented: "Announced ONRAD Acquisition Nicely Expands The Offering And Offers Potential Growth Offshoots; Yesterday post close, RDNT announced the company has entered into an agreement to acquire ONRAD, a leading provider of teleradiology and in-hospital radiology staffing services for ~$700M ($350M cash and 5M shares) plus an earnout of up to $210M. The acquisition will add a third reportable segment for RadNet (Radiology Professional Services), further broaden the company's capabilities, and we think should prove highly synergistic with the legacy businesses while

Form 8-K RadNet, Inc. For: Oct 26

Mon, 26 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261026/27234154.html

RadNet to acquire ONRAD for $350M cash plus stock

Mon, 26 Oct 2026 16:01:11 -0400

RadNet, Inc. (NASDAQ: RDNT) announced it has entered into a definitive agreement to acquire ONRAD, Inc., a provider of teleradiology and in-hospital professional radiology staffing services, for $350 million in cash and 5 million shares of RadNet common stock, subject to customary adjustments.

The transaction also includes an earnout of up to $210 million payable upon achievement of target EBITDA for 2027, which RadNet may satisfy in cash, common stock, or a combination of both. The deal is expected to close in early 2027, pending regulatory review and customary closing conditions.

ONRAD operates through more than 130 contracted radiologists and serves more

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

Mon, 26 Oct 2026 16:01:00 -0400

Adds a radiology professional services platform offering teleradiology and in-hospital staffing for hospitals and health systems
Enables RadNet to seamlessly combine radiology professional services, AI-powered technology solutions and outpatient imaging operations into an integrated offering, transforming radiology workflows and ultimately improving patient care
Uniquely positions RadNet with an expanded offering to address the full range of care settings where imaging is performed inside and outside of hospitals
Acquisition adds to RadNet a capital-light, high-margin management services platform supporting more than 225 hospital facilities across 26 states with more than 130 contracted radiologists
ONRAD is expected to add $190 million to $200 million

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

Mon, 26 Oct 2026 16:01:00 -0400

Adds a radiology professional services platform offering teleradiology and in-hospital staffing for hospitals and health systems
Enables RadNet to seamlessly combine radiology professional services, AI-powered technology solutions and outpatient imaging operations into an integrated offering, transforming radiology workflows and ultimately improving patient care
Uniquely positions RadNet with an expanded offering to address the full range of care settings where imaging is performed inside and outside of hospitals
Acquisition adds to RadNet a capital-light, high-margin management services platform supporting more than 225 hospital facilities across 26 states with more than 130 contracted radiologists
ONRAD is expected to add $190 million to $200 million

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

Thu, 08 Oct 2026 06:00:00 -0400

Multicenter retrospective study finds combining radiologist assessment with DeepHealth’s Prostate AI could reduce biopsies by 18.9% while identifying men with clinically significant prostate cancer with 98.4% sensitivity
SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth’s Prostate MR Solution¹ could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.²

Prostate cancer is

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

Thu, 08 Oct 2026 06:00:00 -0400

Multicenter retrospective study finds combining radiologist assessment with DeepHealth’s Prostate AI could reduce biopsies by 18.9% while identifying men with clinically significant prostate cancer with 98.4% sensitivity
SOMERVILLE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced new findings published in European Radiology supporting that AI applications within DeepHealth’s Prostate MR Solution¹ could help clinicians decide more confidently which men may need a prostate biopsy, particularly when MRI findings are uncertain.²

Prostate cancer is

RadNet partners with WIN-NextGen to recruit youth into medical imaging

Thu, 01 Oct 2026 06:03:04 -0400

RadNet, Inc. (NASDAQ: RDNT) announced a collaboration with WIN-NextGen, a nonprofit workforce development organization, to introduce students and young adults to careers in medical imaging, according to a company press release.
The program targets students aged 12 to 17 in Maryland, Washington, D.C., and parts of Virginia, as well as young adults aged 18 to 24. Participants will have access to WIN-NextGen's digital workforce platform, which includes learning modules, career exploration tools, mentorship opportunities, and shadowing experiences at RadNet imaging centers.
In the program's initial phase, participants who complete learning modules can earn rewards including merchandise, iPads, invitations to RadNet events, and

RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals

Thu, 01 Oct 2026 06:00:00 -0400

New program introduces students and young adults to careers in radiology through mentorship, digital experiences and hands-on learning.

OWINGS MILLS, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in high-quality, cost-effective outpatient diagnostic imaging and a global developer of digital health solutions, today announced a collaboration with WIN-NextGen, a leading workforce innovation network dedicated to cultivating talent across the 3S Workforce™ (STEM, Supply Chain and Skilled Trades), to introduce middle school, high school and young adult learners to careers in medical imaging.

The medical imaging profession is facing a

RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals

Thu, 01 Oct 2026 06:00:00 -0400

New program introduces students and young adults to careers in radiology through mentorship, digital experiences and hands-on learning.

OWINGS MILLS, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in high-quality, cost-effective outpatient diagnostic imaging and a global developer of digital health solutions, today announced a collaboration with WIN-NextGen, a leading workforce innovation network dedicated to cultivating talent across the 3S Workforce™ (STEM, Supply Chain and Skilled Trades), to introduce middle school, high school and young adult learners to careers in medical imaging.

The medical imaging profession is facing a

Raymond James Assumes RadNet (RDNT) at Strong Buy

Mon, 28 Sep 2026 07:22:50 -0400
(Updated - September 28, 2026 7:22 AM EDT)
Raymond James analyst Andrew Cooper assumes coverage on RadNet (NASDAQ: RDNT) with a Strong Buy rating and a price target of $95.00.
The analyst comments "We reiterate our Strong Buy rating on RadNet as it lands at the top of the heap in our provider fundamental quality matrix. The freestanding imaging landscape has winds at its back from potential site neutral payment policies and RadNet is well positioned to capitalize. At the same time that it is posting leading core imaging segment growth, we believe the digital health franchise offers additional optionality that investors

Raymond James Assumes RadNet (RDNT) at Strong Buy

Mon, 28 Sep 2026 07:22:50 -0400
(Updated - September 28, 2026 7:22 AM EDT)
Raymond James analyst Andrew Cooper assumes coverage on RadNet (NASDAQ: RDNT) with a Strong Buy rating and a price target of $95.00.
The analyst comments "We reiterate our Strong Buy rating on RadNet as it lands at the top of the heap in our provider fundamental quality matrix. The freestanding imaging landscape has winds at its back from potential site neutral payment policies and RadNet is well positioned to capitalize. At the same time that it is posting leading core imaging segment growth, we believe the digital health franchise offers additional optionality that investors

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 12:20:06 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Remlifanserin Ph2 ADP data just missed stat sig on the 1o EP of SAPS H+D (p=0.06) but nominal sig on key 2o EP of CGI-S-ADP (p=0.008). ESs were 0.33 and 0.43, respectively, in a prespecified 60mg pt subgroup with higher BL psychosis. Safety was solid. Ph3 enrollment continues; ACAD will remove the 30mg arm and likely enrich for pts with even higher baseline psychosis pending FDA alignment. Our Take: While investor conviction into the Ph2 RADIANT data was middling, we

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Thu, 24 Sep 2026 12:20:06 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Remlifanserin Ph2 ADP data just missed stat sig on the 1o EP of SAPS H+D (p=0.06) but nominal sig on key 2o EP of CGI-S-ADP (p=0.008). ESs were 0.33 and 0.43, respectively, in a prespecified 60mg pt subgroup with higher BL psychosis. Safety was solid. Ph3 enrollment continues; ACAD will remove the 30mg arm and likely enrich for pts with even higher baseline psychosis pending FDA alignment. Our Take: While investor conviction into the Ph2 RADIANT data was middling, we

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Thu, 24 Sep 2026 12:16:58 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a Outperform rating.
The analyst comments "RADIANT miss is a near-term headwind to ACAD shares, but future development remains promising. Clear dose response, consistency of SAPS-H+D improvements over time, and stronger efficacy in higher psychosis burden patients all suggest remlifanserin is therapeutically active in ADP. While we are reducing our target to $34/share on incrementally lower PoS (35% vs. 40% prior), investors should not discount the potential for remlifanserin to show success in both ADP and LBDP. Acadia's strong commercial portfolio remains

Raymond James Reiterates Strong Buy Rating on RadNet (RDNT)

Tue, 22 Sep 2026 06:25:15 -0400

Raymond James analyst John Ransom reiterated a Strong Buy rating and $95.00 price target on RadNet (NASDAQ: RDNT)
The analyst comments "Late last week we hosted a series of investor meetings with RadNet CFO Mark Stolper. The tone was generally confident and comfortable, consistent with recent conference commentary, though several changes in the talk track caught our attention. Most notably, health system JV discussions appear to be increasing in volume, breadth, and depth, while the Digital Health goto-market continues to evolve toward hospital customers and a more modular sales approach. Overall, we continue to view the business as capable of driving

RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

Wed, 09 Sep 2026 06:00:00 -0400

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026 at 07:45 a.m. Eastern Time.

There will be simultaneous and archived webcasts available at https://event.webcasts.com/starthere.jsp?ei=1774392&tp_key=42ec603a4d&tp_special=8

Details for RadNet's Presentation:
https://event.webcasts.com/starthere.jsp?ei=1774392&tp_key=42ec603a4d&tp_special=8

Details for RadNet's Presentation:

StreetInsider.com News Articles

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

Truist Securities Reiterates Buy Rating on RadNet (RDNT)

Form 8-K RadNet, Inc. For: Oct 26

RadNet to acquire ONRAD for $350M cash plus stock

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc.

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

RadNet partners with WIN-NextGen to recruit youth into medical imaging

RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals

RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals

Raymond James Assumes RadNet (RDNT) at Strong Buy

Raymond James Assumes RadNet (RDNT) at Strong Buy

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

Raymond James Reiterates Strong Buy Rating on RadNet (RDNT)

RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026